For Health Care Providers
Clinical Guidance and ResourcesTPOXX
MPX Tecovirimat treatment information for providers
AlCo Health Advisories
Important information about the local MPX epidemic
Intradermal Administration
Interim vaccination guidance
Case Reporting
Confidential Morbidity Report (CMR) Form
CDPH Guidance
Health advisories and resources from CDPH and CDC
CDC Guidance
Information for health care professionals
Clinical Case Recognition of Mpox
Below are resources to support with clinical Mpox case recognition:
Reporting Suspected or Confirmed Cases of Mpox
Report all probable (e.g., positive orthopox virus by PCR) or confirmed Mpox (e.g., positive Mpox virus by PCR) cases to ACPHD within 1 working day by submitting a completed Confidential Morbidity Report (CMR) form by fax to (510) 273-3744.
For any suspect case who has signs or symptoms of Mpox and resides in a congregate setting (e.g., homeless shelter, skilled nursing facility, correctional facility) while testing is pending, please review CDC guidance and ensure individuals can comply with guidance on isolation. Also, please notify ACPHD within 24 hours by calling (510) 267-3250 during business hours Monday through Friday 8AM to 5PM, and (925) 422-7595 after 5PM on weekdays and on weekends.
Case definitions for suspect, probable, and confirmed cases of monkeypox are provided by the CDC here: CDC Case Definitions for Use in the 2022 Monkeypox Response.
Pediatric Mpox Screening Resources
Minor Consent for Mpox Treatment
The Consent to Medical Services for the Treatment of Monkeypox (Mpox) in Minors is now live and can be found within the Information for Health Care Providers and also under the local health jurisdiction (LHJ) subpage, under the section for Vaccines Distribution and Administration.
Mpox Tecovirimat Treatment (TPOXX)
Many patients with mpox have a mild, self-limited disease and recover without medical intervention. Most patients with mpox who require treatment are being managed as outpatients. However, the prognosis for mpox depends on multiple factors, including immune status, previous vaccination, co-morbid, initial health status.
Supportive Care Suggestions should be initiated for all patients who have mpox infection. This may include topical or systemic medications or other clinical interventions to control pain, itching, nausea and vomiting. Patients should be monitored closely to ensure resolution of illness without complications that would require further intervention. Patients with confirmed or suspected mpox should also be screened for human immunodeficiency virus (HIV) and other sexually transmitted infections (STIs).
Patients who are at high risk for severe disease or progress to severe mpox, despite supportive care and treatment, should be considered for prompt tecovirimat treatment. Tecovirimat (also known as TPOXX or ST-246) is an FDA-approved antiviral medication for the treatment of human smallpox disease in adults and children.
The Centers for Disease Control and Prevention (CDC) holds an expanded access Investigational New Drug (EA-IND) protocol that allows for the use of stockpiled tecovirimat to treat mpox during an outbreak. See CDC Guidelines for Tecovirimat Use for more details.